Streetbeat News

Analyst Ratings

IMXI

Needham analyst Mayank Tandon has reiterated a 'Buy' rating on IntL Money Express (NASDAQ:IMXI) and maintained a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:35 am

OB

Needham analyst Laura Martin has reiterated a 'Buy' rating on Outbrain (NASDAQ:OB) and maintained a price target of $5.5.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:35 am

JOBY

Canaccord Genuity has maintained a Buy rating on Joby Aviation's stock and increased its price target from $8 to $11. This has led to a rise in Joby Aviation's share prices.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 10:34 am

NPIFF

National Bank Financial Inc's analyst Rupert Merer has maintained an 'Outperform' rating on Northland Power (OTC:NPIFF) but lowered the price target from C$40 to C$37.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 10:20 am

RLYB

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Rallybio (NASDAQ:RLYB) and maintained an $18 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:18 am

CCL

Tigress Financial analyst Ivan Feinseth maintains a Buy rating on Carnival (NYSE:CCL) and raises the price target from $13 to $23.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 10:18 am

UNCY

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Unicycive Therapeutics (NASDAQ:UNCY) but lowers the price target from $8 to $7.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:17 am

ALDX

HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on Aldeyra Therapeutics (NASDAQ:ALDX) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:16 am

RNLX

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Renalytix (NASDAQ:RNLX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:16 am

PSTV

HC Wainwright & Co. analyst Sean Lee maintains a 'Buy' rating on Plus Therapeutics (NASDAQ:PSTV) and raises the price target from $3.5 to $8.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:15 am